Neurological disorders Archives

News and Trends 18 Aug 2020

Women’s Health Gains Traction as Bayer Pays €736M for UK Firm

Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s health – a historically neglected field in the biotech and pharma industry. Through this deal,…

August 18, 2020 - 3 minutesmins - By Jonathan Smith

sonoran desert toad psychedelic beckley psytech

News and Trends 1 Jul 2020

UK Startup Bags €3M to Develop Psychedelic Medicines for Mental Health

A €3.3M (£3M) Series A round raised by the Oxford-based biomedicine company Beckley Psytech will allow the company to study the use of a psychedelic compound for the treatment of…

July 1, 2020 - 3 minutesmins - By Kostas Vavitsas

News and Trends 11 Jun 2020

Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1B

British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the…

June 11, 2020 - 3 minutesmins - By Helen Albert

huntingtons disease dementia prilenia therapeutics

News and Trends 5 Jun 2020

Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS

Prilenia Therapeutics has raised €55M in Series A funding to launch late-stage clinical trials of its small molecule candidate drug in Huntington’s disease and amyotrophic lateral sclerosis, incurable conditions that…

June 5, 2020 - 3 minutesmins - By Helen Albert

brainvectis askbio gene therapy neurology

News and Trends 28 Apr 2020

AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s

The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy company AskBio. AskBio’s gene therapy experience and…

April 28, 2020 - 3 minutesmins - By David Kirk

News and Trends 21 Apr 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. …

April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt

multiple sclerosis neuron sheath medday Pharma

News and Trends 11 Mar 2020

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial…

March 11, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Feb 2020

Scientists Connect Brain Cells to Machines Over the Internet

An international group of researchers has set up a brain-machine interface between cultured nerve cells and electronic chips linked over the internet, which could lead to the development of AI…

February 27, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Feb 2020

EU Project Set up to Fight Alzheimer’s Disease with Lasers

A project has launched with a €3.6M grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. There are currently no…

February 7, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 4 Feb 2020

Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder

Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a…

February 4, 2020 - 2 minutesmins - By Jonathan Smith

In Depth 9 Dec 2019

As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers?

With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts…

December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Sep 2019

Orchard’s Gene Therapy Improves Children’s Motor Ability

Orchard Therapeutics' gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic…

September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering